Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

Corporate Breaking News

Home : Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

Dec 09 2019	Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
STOCKHOLM, Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented data on the cost effectiveness of Doptelet® (avatrombopag) for the treatment of thrombocytopenia in patients with chronic liver diseases (CLD)...


Source:https://www.prnewswire.com:443/news-releases/doptelet--avatrombopag-demonstrates-cost-effectiveness-for-the-treatment-of-thrombocytopenia-in-patients-with-chronic-liver-disease-300971105.html

Related News
» BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019 » RCShopers Announces Availability of Research Chemicals Online